|
A message from our partners at Huge Alerts
There’s a Good Reason to Watch BSEM Closely After Its Strategic Reset Quarter — And Why the Company’s Expanding Hospital Footprint, Clinical Momentum, and Nasdaq Uplisting Path Could Still Signal Significant Upside Ahead! The latest quarterly report from BioStem Technologies (OTCQB: BSEM) entered may have reflected short-term pressure from acquisition integration costs and margin transition dynamics, but many experienced growth investors are looking beyond the temporary earnings volatility and focusing instead on the broader transformation now underway. Following the BioTissue acquisition, BSEM dramatically increased its commercial reach, accelerated its entry into hospital-based wound care markets, expanded its sales infrastructure, and continued building what management believes can become a fully integrated regenerative medicine platform spanning both chronic and acute wound care applications. At the same time, BSEM continues to operate in some of healthcare’s fastest-growing sectors, including diabetic wound care, surgical recovery, soft tissue repair, and advanced biologic therapies. With prior profitability already demonstrated over multiple quarters (seven actually) proprietary allograft technology differentiating the company from competitors, and analysts citing the potential for substantial valuation expansion if execution continues, speculative investors are increasingly keeping the company on high-alert watchlists throughout 2026. As BSEM continues progressing toward a planned Nasdaq uplisting, investors are closely watching the company for the possibility of increased market visibility, stronger liquidity, and expanded institutional interest. Adding to the bullish sentiment, Zacks Small-Cap Research has previously issued a $25.50 price target on BSEM, highlighting the company’s profitability track record, clinical momentum, and long-term growth opportunity in regenerative medicine and advanced wound care! Discover why BSEM is emerging as one of the most intriguing regenerative medicine transition stories currently developing in the OTC market
Bonus News from MarketBeat.com
As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” TradeReported by Jessica Mitacek. Article Posted: 5/18/2026. 
Key Points
- U.S. federal debt has exceeded 100% of GDP for the first sustained period since 1946, with total national debt topping $39 trillion.
- Two international ETFs, VXUS and IXUS, offer investors a hedge against U.S. sovereign risk by covering 99% of global market capitalization outside the United States.
- Both funds have outperformed the S&P 500 over the past year with gains exceeding 29%, while paying dividend yields above 2.6%.
- Special Report: The worst mistake you can make with the SpaceX IPO
America has a massive debt problem, and it isn’t record-high auto loans and credit card delinquencies that are fueling the crisis. As of March 31, U.S. federal debt held by the public exceeded 100% of the country’s gross domestic product (GDP) for the first sustained period since 1946. According to the U.S. Debt Clock, the national debt has now topped $39 trillion, and the interest on that debt exceeds $1 trillion. Meanwhile, Federal Reserve data indicates that in Q1 2026, U.S. GDP was nearly $32 trillion.
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst environment in 50 years - with portfolios potentially staying in the red for 10 years or longer.
From rate spikes in 2022 to $12 trillion wiped out in 30 days during the Iran War, Wall Street suggests the volatility isn't slowing down. TradeSmith CEO Keith Kaplan is showing investors what steps to take now to prepare their wealth before this worsens. Click here to learn how to defend your portfolio before this hits
As sovereign risk rises, conservative-minded investors can turn to two exchange-traded funds (ETFs) that may help hedge against the possibility of a federal debt default. How U.S. Federal Debt Got So BadSave for a very brief period during the pandemic, when GDP plummeted, the last time the United States found itself in this situation was in the wake of World War II. But unlike post-war America, the drivers and implications today are far different. According to the Peter G. Peterson Foundation, a nonpartisan, nonprofit organization that aims to build support for solutions to put America on a sustainable fiscal path, today’s federal debt crisis is being driven by a combination of factors. A series of tax cuts, and the resulting lower tax revenue, increased government spending, interest payments, and the costs associated with America’s aging population have fueled a rise in both Social Security and Medicare outlays. The Congressional Budget Office (CBO) anticipates that federal spending will rise from 23.3% of GDP in 2026 to 27.9% in 2056. The CBO has also found that while tax revenue will also increase during that forecast period, it will do so more slowly, climbing from 17.5% of GDP in 2026 to 18.8% in 2056. While the United States has yet to default on its debt, government shutdowns spurred by deficit-spending debates have contributed to the country’s credit rating being downgraded three times. Most recently, Moody’s lowered the U.S. rating from Aaa to Aa1 in 2025, citing rising debt and the interest costs of servicing that debt. Previously, Fitch Ratings and Standard & Poor’s downgraded the United States’ credit rating in 2023 and 2011, respectively. For investors who are growing increasingly wary of sovereign risk in the United States—which could adversely affect U.S.-based companies—ETFs that specifically target global exposure can provide a layer of safety. Vanguard’s Global Diversification PlayThe Vanguard Total International Stock ETF (NASDAQ: VXUS) is designed to track the FTSE Global All Cap ex US index, a market-cap-weighted index of global stocks covering 99% of the world's market capitalization outside the United States. Launched in January 2011, the ETF has performed particularly well since COVID-19 disrupted global markets. Since the fund’s March 2020 pandemic low, it has gained 120%. But since the “Sell America” trade emerged in April 2025 and accelerated through the fall as the market rotated out of high-flying tech stocks and mega-cap U.S. equities, the fund has performed particularly well. Over the past year, the Vanguard Total International Stock ETF has gained around 25%, outperforming both the S&P 500 and the Dow Jones Industrial Average. That’s been driven by lopsided institutional ownership, with 1,342 buyers injecting more than $10 billion into the fund over the past 12 months compared with 671 sellers pulling out just over $4 billion. Particularly appealing to income investors, VXUS pays an annual dividend of $2.28 per share. Current short interest is negligible at 0.48% of the float, or just 8.4 million shares out of the 1.73 billion shares outstanding. While the absence of U.S.-listed equities may suggest limited growth prospects, VXUS's top-10 holdings include growth stocks like Taiwan Semiconductor Manufacturing Company (NYSE: TSM) and new trillion-dollar market cap member Samsung (OTCMKTS: SSNLF), in addition to global Big Pharma mainstays Novartis (NYSE: NVS) and AstraZeneca (NYSE: AZN). BlackRock’s International Equity HedgeLike VXUS, the iShares Core MSCI Total International Stock ETF (NASDAQ: IXUS) is designed to provide exposure to global stocks by covering 99% of the global market cap outside the United States. Since its debut in October 2012, it has tracked the market-cap-weighted MSCI AC World ex USA IMI Index. Since the fund’s pandemic low, it has gained nearly 129%. The fund has outperformed the S&P 500 over the past year, with a gain of around 25%. IXUS pays an annual dividend of $2.74, slightly more than its VXUS counterpart. But the spread between institutional buying and selling is even more pronounced for IXUS. Over the past year, the fund has seen inflows of over $1 billion versus outflows of less than $228 million. Current short interest of 1.32% of the float is higher than VXUS, but still suggests the fund isn’t on bears’ radar. The ETF’s top-10 holdings also include Taiwan Semiconductor, Samsung, Novartis, and AstraZeneca, while providing additional Asian exposure via Alibaba (NYSE: BABA) and Tencent Holdings (NYSE: TME). |
